1. Home
  2. News
  3. Noxopharm Ltd.
  4. Novel Dual-cell Therapy Results in Pancreatic Cancer
More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

Novel Dual-cell Therapy Results in Pancreatic Cancer

Sep 13, 2022 at 10:29 PM EDT · Issued by Noxopharm Ltd.

Filed with ASX · Sep 13, 2022 at 10:29 PM EDT · 8 pages · English

On 6ix: 6ix.com/news/novel-dual-cell-therapy-results-in-pancreatic-cancer

Noxopharm Ltd. on 6ix

Earlier from Noxopharm

  • Response to ASX Price QuerySep 1, 2022
  • June 2022 Quarterly Activities Report and Appendix 4CJul 26, 2022
  • March 2022 Quarterly Activities Report and Appendix 4CApr 27, 2022
  • FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma TreatmentMar 29, 2022
  • Orphan Drug Designation Granted to Noxopharm by US FDAMar 21, 2022

Later from Noxopharm

  • September 2022 Quarterly Activities Report and Appendix 4COct 20, 2022
  • NOX Pipeline Boosted by $1.5M Grant to Hudson InstituteDec 15, 2022
  • DARRT-2 Trial Efficacy Phase to CommenceJan 16, 2023
  • December 2022 Quarterly Activities Report and Appendix 4CJan 26, 2023
  • Appendix 4D and Half Year 2023 Financial ReportFeb 24, 2023
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer